🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

NLS Pharmaceutics submits plan to meet Nasdaq compliance requirements

EditorEmilio Ghigini
Published 02/23/2024, 08:36 PM
© Reuters.
NLSP
-

ZÜRICH - NLS Pharmaceutics Ltd. (NASDAQ:NLSP), a Swiss biopharmaceutical company, has submitted a plan to regain compliance with the Nasdaq Capital Market's minimum stockholders' equity standard. The company, which specializes in developing treatments for central nervous system disorders, faced non-compliance after receiving a notification from Nasdaq on January 9, 2024.

Nasdaq Listing Rule 5550(b)(1) stipulates that companies must maintain stockholders' equity of at least $2.5 million. NLS's submission of the compliance plan was timely, and if approved, Nasdaq may allow up to 180 days, until July 8, 2024, for the company to demonstrate adherence to the listing rule.

Founded in 2015, NLS Pharmaceutics is engaged in the discovery and development of novel therapies for patients with rare and complex neurological conditions. The company operates globally, collaborating with a network of partners and scientists to address unmet medical needs.

The press release also includes forward-looking statements regarding the company's potential to regain compliance with Nasdaq's continued listing requirements. However, these statements are subject to various factors and uncertainties that could cause actual results to differ from those projected. NLS has cautioned that changes in technology, market requirements, and potential delays in clinical trials, among other risks, could impact their operations and the validity of these forward-looking statements.

This development is based on a press release statement and reflects the company's current efforts to maintain its position on the Nasdaq Capital Market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.